Structural Determinants of μ-Opioid Receptor Antagonism and Respiratory Liability in Phenylfentanyl Analogues
Open Access
- 30 April 2026
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 17 (10) , 1888-1908
Abstract
The μ-opioid receptor (MOR) plays a key role in opioid addiction and fentanyl-induced respiratory depression. Phenylfentanyl, previously reported as a MOR antagonist, paradoxically induces respiratory depression in vivo, revealing a dissociation between receptor antagonism and respiratory liability within this scaffold. To interrogate structural determinants underlying this activity profile, phenylfentanyl was redesigned through systematic modification of the acyl chain, N-alkyl group, and core ring scaffold, including exploration of a 6,6-ring extension to probe the MOR binding space. Seventy-eight compounds were synthesized and evaluated. The 6,6-ring series exhibited markedly reduced MOR activity relative to the 6-membered core analogues, likely due to suboptimal pharmacophore spacing. Among these, compound 5 demonstrated solid MOR antagonist activity, effectively blocking morphine- and fentanyl-induced antinociception in vivo and showing greater potency than phenylfentanyl in vitro. Importantly, compound 5 did not induce respiratory depression at the tested dose, indicating a lack of intrinsic respiratory liability. These findings delineate structural features governing MOR antagonism and respiratory effects within a fentanyl-derived scaffold.Keywords
Funding Information
- National Institute on Drug Abuse (P30DA033934)
- National Institute on Drug Abuse (UG3DA054785)
This publication has 32 references indexed in Scilit:
- Clinical Pharmacokinetics and Pharmacodynamics of NaloxoneClinical Pharmacokinetics, 2024
- Molecular recognition of morphine and fentanyl by the human μ-opioid receptorCell, 2022
- Respiratory depressant effects of fentanyl analogs are opioid receptor-mediatedBiochemical Pharmacology, 2021
- Exploring naltrexamine derivatives featuring azaindole moiety via nitrogen-walk approach to investigate their in vitro pharmacological profiles at the mu opioid receptorBioorganic & Medicinal Chemistry Letters, 2021
- Efflux mechanism and pathway of verapamil pumping by human P-glycoproteinArchives of Biochemistry and Biophysics, 2020
- Computational insights into the molecular mechanisms of differentiated allosteric modulation at the mu opioid receptor by structurally similar bitopic modulatorsJournal of Computer-Aided Molecular Design, 2020
- Binding mode analyses of NAP derivatives as mu opioid receptor selective ligands through docking studies and molecular dynamics simulationBioorganic & Medicinal Chemistry, 2017
- Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3′-carboxamido)morphinan analogues as opioid receptor ligandsBioorganic & Medicinal Chemistry, 2015
- Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. CohenJournal of Molecular Biology, 1997
- Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizoleFEBS Letters, 1996